2023-2030 年胸導管的全球市場

市場概覽

在預測期內 (2023-2030)，全球胸導管市場規模預計將以 6.2% 的複合年增長率增長。

胸導管是一種柔性管，通過胸部的切口（切口）插入胸部。 導管放置在胸膜腔內，並有許多孔以收集多餘的液體。 胸腔導管被用作一線治療，以提高患者的生活質量、患者安全、臨床醫生的效率、避免住院治療，並以最少的干預有效緩解症狀。

市場動態

當胸膜固定術失敗或禁忌時，胸腔導管插入術作為惡性胸腔積液的一種治療選擇正變得越來越流行。 胸導管插入術被用作一線治療，以提高患者的生活質量、安全性和臨床醫生的效率。 消除住院並以最少的干預實現有效的症狀緩解是推動胸導管市場增長的關鍵因素。

全球心血管疾病患病率的上升預計將推動市場增長。

根據美國疾病控制和預防中心的數據，到 2020 年，心髒病將導致 382,□□776 名男性（四分之一的男性）和 314,186 名女性（五分之一的女性）死亡。 CVD是指一組心臟和血管疾病，包括冠狀動脈疾病、腦血管疾病和風濕性心髒病。 超過五分之四的 CVD 死亡是由於心髒病發作和中風，其中三分之一在 70 歲之前過早死亡。

胸腔積液最常見的原因是充血性心力衰竭 (CHF)。 當胸膜微循環中增加的靜水壓力超過淋巴管重吸收多餘液體的能力時，胸腔積液就會積聚在胸膜腔中。 大約 70% 的 CHF 患者會出現胸腔積液，但通常會在治療基礎疾病後重新吸收。 在有症狀的患者中，在等待藥物治療反應時通常考慮進行治療性胸腔穿刺術。 儘管進行了最佳的醫療管理，患者仍可能會反復出現有症狀的胸腔積液。 因此，留置胸腔導管治療充血性心力衰竭有效、耐受性好、並發症發生率低，可能是一種合理的治療方法，尤其是對於非移植患者。 預計上述所有因素都將在預測期內推動市場。

與胸導管相關的並發症預計會阻礙市場增長。

胸腔導管常用於患有復發性心臟相關慢性疾病的患者。 雖然它可以很容易地插入而無需鎮靜，但它的使用與許多並發症有關。 導管相關性胸膜感染在患者中最常見。 與使用胸導管相關的其他風險包括導管導管轉移、嚴重胸痛和導管脫位。 這些與胸導管長期存在於體內相關的並發症會給患者帶來問題並阻礙市場增長。

COVID-19 影響分析

COVID-19 大流行給胸膜疾病管理帶來了新的挑戰。 由於資源和人員被轉移到急性病 COVID-19 患者的管理上，胸膜疾病的常規醫療實踐和服務提供受到嚴重干擾。 這也對胸膜癌和肺癌服務的提供造成了嚴重干擾，並且正在定期更新指南以反映這種流行病不斷變化的情況。 例如，英國胸科學會 (BTS) 的 COVID-19 建議建議在確保患者和工作人員安全的同時減少醫院就診和住院治療。提倡繼續診斷途徑。 此外，我們建議有症狀的惡性胸腔積液患者接受治療性大容量抽吸或一線留置胸腔導管 (IPC)，以避免需要住院進行胸腔引流或滑石粉胸膜固定術。我在這裡。 應培訓家庭盡可能排除 IPC，以減少與多次訪問地區護士相關的風險。 根據當地的專業知識，適合化療的癌症患者應接受日間護理胸腔鏡檢查或影像引導胸膜活檢，有或沒有 IPC。 因此，從上述因素來看，預計在預測期內市場將受到影響和改善。

內容

第1章研究方法與範圍

• 調查方法
• 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第4章市場動態

• 市場影響因素
  • 司機
    • 由於全球心血管疾病的增加，預計市場會增長。
  • 約束因素
    • 預計與胸導管相關的並發症會阻礙市場增長。
  • 機會
  • 影響分析

第5章行業分析

• 搬運工的五種力量
• 供應鏈
• 定價分析

第 6 章 COVID-19 分析

• COVID-19 市場分析
  • COVID-19 之前的市場情景
  • COVID-19 的當前市場情景
  • COVID-19 後或未來情景
• COVID-19 期間的價格動態
• 供需範圍
• 大流行期間與市場相關的政府舉措
• 製造商的戰略舉措
• 總結

第 7 章適應症

• 惡性胸腔積液
• 非惡性複發性胸腔積液
• 幽門胸膜炎
• 腦水腫
• 血胸

最終用戶第 8 章

• 醫院
• 門診手術中心
• 其他

第9章按地區

• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 意大利
  • 西班牙
  • 其他歐洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 其他亞太地區
• 中東和非洲

第10章競爭格局

• 競爭場景
• 市場情況/份額分析
• 併購分析

第11章公司簡介

• 美敦力
  • 公司簡介
  • 產品組合和說明
  • 主要亮點
  • 財務摘要
• Teleflex Incorporated
• Ply Gem Holdings Inc
• Smiths Group plc
• Medela AG
• ATMOS MedizinTechnik GmbH & Co. KG
• ARGON MEDICAL
• BD
• MAQUET Holding B.V. & Co. KG
• LivaNova PLC
• Cook Medical

第 12 章全球胸導管市場-DataM

Market Overview

The global pleural catheters market size was valued US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of 6.2% during the forecast period (2023-2030).

The pleural catheter is a flexible tube inserted through an incision (cut) in the chest and placed in the pleural cavity. The catheter sits in the pleural cavity and has many holes to collect the extra fluid. Pleural catheters are used as a first-line therapy to improve patient quality of life, patient safety, and clinician efficiency-freedom from hospitalization and effective symptomatic relief with minimal interventions.

Market Dynamics

Pleural catheters are becoming more popular worldwide as a treatment option for malignant pleural effusions when pleurodesis has failed or is contraindicated. Pleural catheters are used as first-line therapy to improve patient quality of life, safety, and clinician efficiency. Some critical factors driving the growth of the pleural catheter market include eliminating hospital admissions and providing effective symptomatic relief with minimal interventions.

The increasing prevalence of the cardiovascular disease worldwide is expected to drive market growth.

According to the Centers for Disease Control and Prevention, 2020, heart disease killed 382,776 men (1 in 4 male deaths) and 314,186 women (1 in 5 female deaths). CVDs are a group of heart and blood vessel disorders, including coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other conditions. More than four of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths occur prematurely in people under 70.

The most common cause of the pleural effusion is congestive heart failure (CHF). When increased hydrostatic pressure in the pleural microcirculation exceeds the capacity of lymphatic vessels to reabsorb the excess fluid, fluid accumulates in the pleural space. Although pleural effusion occurs in approximately 70% of CHF patients, treatment of the underlying disease usually results in fluid reabsorption. In symptomatic patients, therapeutic thoracentesis is frequently considered while waiting for a pharmacological treatment effect. Patients may experience recurrent symptomatic pleural effusions despite optimal medical management. Therefore, indwelling pleural catheters are effective and well tolerated in congestive heart failure, have a low complication rate, and may be considered a reasonable treatment option, particularly for nontransplant candidates. Thus, from the above factors, the market is expected to drive in the forecast period..

Complications Associated with pleural catheters are expected to hamper the market growth.

Pleural catheters are commonly used in patients suffering from recurrent heart-related chronic diseases. Although they are simple to insert without sedation, many complications are associated with their use. Catheter-related pleural infections are the most common in patients. Other risks associated with using pleural catheters in patients include catheter tract metastases, severe chest pain, tube dislocation, etc. Such complications related to the long-term presence of pleural catheters in the body can cause problems for patients, hampering market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has created new challenges for pleural disease management. Routine medical practice and service provision for pleural diseases have been severely disrupted as resources and personnel have been redirected to manage acutely ill COVID-19 patients. This has also resulted in significant disruptions in the delivery of pleural and lung cancer services, with guidelines being updated regularly to reflect the ever-changing landscape of this pandemic. For instance, the British Thoracic Society (BTS) COVID-19 recommendations advocate for the continuation of diagnostic pathways for suspected cancer to reduce hospital visits and admissions while ensuring patient and staff safety. Moreover, patients with symptomatic malignant pleural effusions are advised to undergo either large-volume therapeutic aspirations or first-line indwelling pleural catheters (IPC), avoiding the need for hospitalization for chest drain and talc pleurodesis. Family members should be trained to drain IPCs whenever possible, reducing the risks posed by multiple district nurse visits. Depending on local expertise, patients with cancer who are candidates for anti-cancer therapy should have a day-case medical thoracoscopy with/without an IPC or image-guided pleural biopsies. Thus, from the above factors, the market got affected and is expected to improve in the forecast period.

Segment Analysis

Malignant Pleural Effusions segment is expected to hold the largest market share in pleural catheters

The malignant pleural effusions segment accounted for the largest market share in 2021. Many diseases can cause pleural effusion. It has been observed in infections, other diseases, and cancers. In general, fluid accumulates in the pleural space when there is an excess of fluid, a decrease in fluid absorption, or both. If the effusion is caused by cancer cells in the fluid, it is referred to as a "malignant pleural effusion" or MPE. When cells from lung cancer or another type of cancer spread to the pleural space, an MPE forms. These cancer cells increase pleural fluid production while decreasing fluid absorption.

Furthermore, people with lung cancer, breast cancer, and lymphoma (lymphatic tissue cancer) are more likely to get an MPE. Another common cause of MPE is mesothelioma (a rare cancer of the pleura). MPE can also be caused by cancer that has spread from the stomach, kidney, ovaries, or colon. Therefore, the increasing prevalence of cancer worldwide is expected to drive market growth in the forecast period. For instance, according to GLOBOCAN 2020, the number of new cancer cases diagnosed in 2020 is estimated to be 19.3 million, with nearly 10.0 million deaths due to cancer. GLOBOCAN predicts that cancer cases will reach 28.4 million by 2040. Female breast cancer has surpassed lung cancer as the most common cancer in the world (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), and stomach (5.6%).

Additionally, in terms of cancer-related mortality, lung cancer is the leading cause, accounting for 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%). Men are more likely to develop lung, prostate, and colorectal cancers, whereas women are more likely to develop breast, colorectal, and lung cancers. The top ten cancers account for more than 60% of cancer incidence and 70% of cancer mortality. As a result, the demand for indwelling pleural catheters (IPC) has increased because this device is a small catheter placed under your skin and into the pleural fluid, allowing for repeated drainage at home (without any more needle sticks) to relieve symptoms. These catheters are placed as an outpatient procedure under local anesthesia. The catheter is safe and simple to use and may eventually allow the lung to expand fully up to the chest wall. After the fluid buildup subsides, many patients can have the catheter removed after 2-3 months. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global pleural catheters market

North America region accounted for the largest market share in 2021. The increasing prevalence of pleural diseases, rising cases of cardiovascular disease, cancer and infectious disease, increasing number of thoracic surgeries, increasing demand for minimally invasive processes and favorable reimbursement policies are the factors to drive the market in the forecast period. For instance, according to the National Center For Biotechnology Information Report 2022, pleural effusion is the most common pleural disease, affecting 1.5 million patients in the United States annually. Pleural effusions can be caused by a variety of conditions, including lung diseases such as pneumonia and asbestos exposure, systemic diseases such as lupus and rheumatoid arthritis, or the pleural manifestation of diseases that affect other organs such as congestive heart failure, pancreatitis, or conditions local to the pleura such as pleural infections and mesothelioma. Therefore, it has increased the demand for pleural catheters. Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the pleural catheters market are Medtronic, Teleflex Incorporated, Ply Gem Holdings Inc, Smiths Group plc, Medela AG, ATMOS MedizinTechnik GmbH & Co. KG, ARGON MEDICAL, BD, MAQUET Holding B.V. & Co. KG, LivaNova PLC and Cook Medical.

Teleflex Incorporated:

Overview:

Teleflex Incorporated is an American provider of specialty medical devices for various critical care and surgical procedures. The firm reports seven segments: vascular access, interventional, surgical, anesthesia, interventional urology, original-equipment manufacturing, and all others. Teleflex is the home of Arrow, Deknatel, LMA, Pilling, QuikClot, Rusch, UroLift and Weck - trusted brands united by a common sense of purpose. The company's geographic exposure is predominantly in the United States, accounting for 60% of revenue, with overseas markets accounting for the remaining 40%.

Product Portfolio:

Arrow-Clarke Thoracentesis Device: The Arrow-Clarke Thoracentesis Device permits the removal of fluids from the pleural space and provides access to infuse chemotherapeutic or sclerosing agents.

The global pleural catheters market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The increasing prevalence of the cardiovascular disease worldwide is expected to drive market growth.
  • 4.1.2. Restraints:
    • 4.1.2.1. Complications Associated with pleural catheters are expected to hamper the market growth.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces
• 5.2. Supply Chain
• 5.3. Pricing Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Indication

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
  • 7.1.2. Market Attractiveness Index, By Indication
• 7.2. Malignant Pleural Effusions*
  • 7.2.1.1. Introduction
  • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Non-Malignant Recurrent Effusions
• 7.4. Chylothorax
• 7.5. Empyema
• 7.6. Haemothorax

8. By End user

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 8.1.2. Market Attractiveness Index, By End user
• 8.2. Hospitals*
  • 8.2.1.1. Introduction
  • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Ambulatory Surgical Center
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Medtronic*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Teleflex Incorporated
• 11.3. Ply Gem Holdings Inc
• 11.4. Smiths Group plc
• 11.5. Medela AG
• 11.6. ATMOS MedizinTechnik GmbH & Co. KG
• 11.7. ARGON MEDICAL
• 11.8. BD
• 11.9. MAQUET Holding B.V. & Co. KG
• 11.10. LivaNova PLC
• 11.11. Cook Medical

LIST NOT EXHAUSTIVE

12. Global Pleural Catheters Market- DataM

• 12.1. Appendix
• 12.2. About Us and Applications
• 12.3. Contact Us